Galena Biopharma launches a cancer patient registry study

|About: Galena Biopharma, Inc. (GALE)|By:, SA News Editor

Galena Biopharma (GALE +3%) gains today after saying it's started a cancer patient registry study to be known as RELIEF: Rapid Evaluation of Lifestyle, Independence, and Elimination of breakthrough cancer pain with Freedom from oral discomfort through the use of Abstral Sublingual Tablets. RELIEF is a post-marketing multi-center trial to assess its Abstral medication for breakthrough cancer pain in opioid-tolerant cancer patients.